Level of β-amyloid peptide in cerebrospinal fluid of patients with multiple sclerosis and clinically isolated syndrome and its significance
- Author:
- No author available
- Journal Title:
- CHINESE JOURNAL OF NEUROMEDICINE
- Issue:
- 7
- DOI:
- 10.3760/cma.j.issn.1671-8925.2011.07.009
- Key Word:
- 多发性硬化;临床孤立综合征;β-淀粉样肽;轴突损伤;Multiple sclerosis;Clinically isolated syndrome;β-amyloid peptide;Axonal damage
Abstract： Objective To investigate the concentration of β-amyloid peptide 42 (Aβ42) in cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS) and its first clinical event-clinically isolated syndrome (CIS), and explore its associations with duration, disability severity and total T2-hyperintense lesion numbers in MRI. Methods Thirty-three patients with MS, 23 patients with CIS and 13 controls were investigated in this study. The disability severity of patients with MS and CIS in attack period was assessed by Expanded Disability Status Scale (EDSS). MRI scanning of brain, spinal cord or optic nerve was performed. And Aβ42 concentration in CSF was assessed by liquid chip assay. Results No significant differences of Aβ42 concentrations in CSF from patients with MS and CIS in attack period were noted as compared with those from controls ([104.78±13.73]pg/mL, [134.13±25.06] pg/mL vs. [137.02±23.35]pg/mL, P>0.05). ButAβ42 concentration in CSF from patients with secondary progressive MS (SPMS, [167.99±36.39]pg/mL) was significantly higher than that from patients with relapsing-remitting MS (RRMS, [92.74±13.64] pg/mL, P=0.042). No correlations of Aβ42 concentration in CSF with the duration of MS and CIS and scores of EDSS were noted in patients with MS and CIS (P> 0.05). The concentration of Aβ42 in CSF from patients with MS with a duration for more than one year lower than the ones with a duration for less than one year, but the difference was not significant (P>0.05). Total T2-hyperintense lesion numbers in MRI of patients with MS and CIS were positively correlated with Aβ42 concentration in CSF (MS patients: r=0.507, P=0.038; CIS patients:r=0.485,P=0.049). Aβ42 concentration in CSF from patients with MS with total T2-hyperintense lesions ≥4 (129.34±19.96) was significantly higher than that from the ones with total T2-hyperintense lesions <4 (73.51±12.60, P=0.049). Conclusion Axonal damage in patients with SPMS is more severe than that in patients with RRMS.Increased CSF Aβ42-level in patients with MS is a feature of disease progression. There is a possible relation between T2-hyperintense lesion load and axonal damage in patients with MS.
- [1]樊红翠,马存根.Th17细胞与多发性硬化/实验性自身免疫性脑脊髓炎[J].2010,(7).
- [2]Giunti D,Uccelli A,Roccatagliata L,etc.Demyelination and axonal damage in a non-human primate model of multiple sclerosis.[J].2001,184(1).
- [3]Fahmy, Aboul-Enein,Martin, Krssák,Romana, H?ftberger,etc.Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla.[J].2010,5(7).
- [4]Barkhof F,Lazeron RH,Thompson EJ,etc.Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.[J].2003,60(2).
- [5]A M, Pascual-Lozano,M C, Martínez-Bisbal,I, Boscá-Blasco,etc.[Total brain T2-hyperintense lesion-volume and the axonal damage in the normal-appearing white matter of brainstem in early lapsing-remitting multiple sclerosis].[J].1900,45(8).
- [6]Casanova B,Pascual AM,Marti-Bonmati L,etc.Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis.[J].2007,69(1).
- [7]B D, Trapp,J, Peterson,R M, Ransohoff,etc.Axonal transection in the lesions of multiple sclerosis.[J].1998,338(5).
- [8]Brundin L,Norgren N,Bouwman F,etc.Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.[J].2009,72(15).
- [9]Gveric D,Keir G,Lazeron RH,etc.Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations.[J].2002,125(Pt.7).
- [10]Axelsson M,Mattsson N,Haghighi S.Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.[J].2009,15(4).
- [11]Tumani H,Brettschneider J,Petzold A,etc.Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.[J].2006,12(2).
- [12]Lange P,Sattler MB,Kohler A,etc.Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis.[J].2008,436(1).
- [13]Cardoso MI,Guimaraes I,Sa MJ.Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.[J].2006,12(3).
- [14]Martin, Valis,Radomir, Talab,Pavel, Stourac,etc.Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.[J].2008,29(6).
- [15]Thompson A,Filippi M,Barkhof F,etc.Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.[J].2005,4(5).
- [16]B, Ferguson,M K, Matyszak,M M, Esiri,etc.Axonal damage in acute multiple sclerosis lesions.[J].1997,120 ( Pt 3).
- [17]Nelson SJ,Antel JP,Zamvil SS,etc.MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy.[J].2003,74(7).
- [18]Bitsch A,Kuhlmann T,Bruck W,etc.Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time.[J].2002,125(Pt.10).
- [19]Latronico N,Colucci M,Mancardi GL,etc.The 14-3-3 protein in multiple sclerosis: a marker of disease severity.[J].2004,10(5).
- [20]Tumani H,Arda S,Brettschneider J,etc.Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis.[J].2005,11(3).
- [21]Schuchardt J,Bunkowski S,Bruck W,etc.Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation.[J].2000,123(Pt.6).
- [22]Kurne A,Calguneri M,Karlioguz K,etc.A clinically isolated syndrome: A challenging entity: Multiple sclerosis or collagen tissue disorders: Clues for differentiation.[J].2008,255(11).